Current GLP-1 drugs for diabetes and obesity management often require frequent injections due to their short half-life. In just two weeks, IPA's LENS ai generated, developed and optimized novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback